{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "marketState": "PRE", "exchange": "NCM", "regularMarketChangePercent": 5.109493, "regularMarketPrice": 1.44, "firstTradeDateMilliseconds": 1422541800000, "priceHint": 4, "earningsTimestamp": 1683806401, "earningsTimestampStart": 1691092800, "earningsTimestampEnd": 1691438400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -13.77, "epsForward": -8.36, "epsCurrentYear": -8.93, "priceEpsCurrentYear": -0.1612542, "sharesOutstanding": 2468920, "bookValue": 4.603, "fiftyDayAverage": 1.82342, "fiftyDayAverageChange": -0.38342, "fiftyDayAverageChangePercent": -0.21027519, "twoHundredDayAverage": 2.91445, "twoHundredDayAverageChange": -1.4744499, "twoHundredDayAverageChangePercent": -0.50591016, "marketCap": 3840696, "forwardPE": -0.17224881, "priceToBook": 0.31283945, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.0 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "shortName": "Salarius Pharmaceuticals, Inc.", "longName": "Salarius Pharmaceuticals, Inc.", "messageBoardId": "finmb_330031056", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChange": 0.07000005, "regularMarketTime": 1684180788, "regularMarketDayHigh": 1.47, "regularMarketDayRange": "1.36 - 1.47", "regularMarketDayLow": 1.36, "regularMarketVolume": 44175, "regularMarketPreviousClose": 1.37, "bid": 0.0, "ask": 0.0, "bidSize": 30, "askSize": 8, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 1.47, "averageDailyVolume3Month": 97846, "averageDailyVolume10Day": 407320, "fiftyTwoWeekLowChange": 0.37, "fiftyTwoWeekLowChangePercent": 0.34579438, "fiftyTwoWeekRange": "1.07 - 7.2", "fiftyTwoWeekHighChange": -5.7599998, "fiftyTwoWeekHighChangePercent": -0.8, "fiftyTwoWeekLow": 1.07, "fiftyTwoWeekHigh": 7.2, "dividendDate": 1563753600, "displayName": "Salarius Pharmaceuticals", "symbol": "SLRX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "2450 Holcombe Boulevard", "address2": "Suite X", "city": "Houston", "state": "TX", "zip": "77021", "country": "United States", "phone": "832 834 6992", "website": "https://www.salariuspharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Mr. David J. Arthur M.B.A.", "age": 59, "title": "CEO, Pres & Director", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 729575, "fmt": "729.58k", "longFmt": "729,575"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mark J. Rosenblum CPA", "age": 69, "title": "Exec. VP of Fin. & CFO", "yearBorn": 1953, "fiscalYear": 2022, "totalPay": {"raw": 409975, "fmt": "409.98k", "longFmt": "409,975"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Nadeem Q. Mirza M.D., M.P.H.", "title": "Sr. VP of Clinical Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Daniela Y. Santiesteban", "title": "Director of Targeted Protein Degradation Program", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}